Thetis Pharmaceuticals is developing TP‑317, an oral BL T1 agonist that activates Resolvin E1 pathways to restore immune homeostasis in inflammatory bowel disease and advanced solid tumors. Leveraging its HEALER™ chemistry platform, TP‑317 is delivered as a stable, water‑soluble enteric‑coated tablet and has demonstrated safety, target engagement, and preclinical efficacy in barrier protection and tumor immunogenicity.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TLFounders
Product
Problem
Current treatments for inflammatory bowel disease (IBD) and advanced solid tumors rely on broad immunosuppression or checkpoint inhibition, which often produce serious infections, limited durability, and suboptimal response rates, leaving a large patient population without effective, disease‑modifying options.
Solution
Thetis Pharmaceuticals is advancing TP‑317, an oral BL T1 (leukotriene B4 receptor 1) agonist that leverages the pro‑resolving lipid mediator Resolvin E1 to restore immune homeostasis. TP‑317 is formulated as a stable, highly water‑soluble amino‑acid chelate salt using the proprietary HEALER™ chemistry platform, enabling reliable enteric‑coated tablet delivery to the upper intestine and systemic exposure. In preclinical models, TP‑317 enhances intestinal barrier integrity, promotes phagocytic clearance of debris, and down‑regulates pro‑inflammatory cytokines in IBD, while in tumor models it stimulates antigen presentation and converts immunologically “cold” lesions to “hot,” augmenting anti‑tumor immunity. A Phase 1a study in healthy volunteers demonstrated favorable safety, tolerability, and target‑engagement pharmacokinetics, positioning TP‑317 for first‑in‑class oral therapy development in both IBD and solid‑tumor indications.
Target Audience
Primary customers are gastroenterology and oncology clinicians seeking disease‑modifying oral therapies for moderate‑to‑severe IBD and advanced solid tumors, as well as pharmaceutical partners interested in co‑development or licensing of a first‑in‑class BL T1 agonist platform.
Features
- BL T1 agonist with biased signaling that selectively activates Resolvin E1 pathways while antagonizing pro‑inflammatory LTB4 signaling.
- HEALER™ platform chemistry converts labile Resolvin E1 lipids into a stable amino‑acid chelate salt, improving aqueous solubility and shelf‑life.
- Enteric‑coated oral tablet formulation ensures release in the upper intestine for optimal absorption and systemic delivery.
- Mechanistic actions include barrier protection, enhanced phagocytosis, cytokine down‑regulation, and reduced leukocyte extravasation in IBD.
- In oncology, TP‑317 up‑regulates dendritic‑cell and tumor‑cell antigen presentation, fostering CD8⁺ T‑cell infiltration and synergizing with checkpoint inhibitors or chemotherapy.
- Preclinical efficacy demonstrated across Crohn’s disease, ulcerative colitis, colorectal, lung, melanoma, and pancreatic cancer models.
- Phase 1a clinical data show a clean safety profile, dose‑proportional exposure, and confirmed pharmacodynamic activity.
- Broad composition‑of‑matter patent portfolio covering the HEALER™ chemistry and TP‑317 molecule in major jurisdictions.